[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lenz Therapeutics Inc (LENZ)

Lenz Therapeutics Inc (LENZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,827
  • Shares Outstanding, K 31,354
  • Annual Sales, $ 19,090 K
  • Annual Income, $ -82,130 K
  • EBIT $ -118 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.58
  • Price/Sales 10.41
  • Price/Cash Flow N/A
  • Price/Book 0.81

Options Overview Details

View History
  • Implied Volatility 191.56% (+77.32%)
  • Historical Volatility 85.55%
  • IV Percentile 98%
  • IV Rank 47.79%
  • IV High 332.82% on 06/16/26
  • IV Low 62.29% on 08/14/25
  • Expected Move (DTE 28) 1.14 (18.52%)
  • Put/Call Vol Ratio 2.84
  • Today's Volume 753
  • Volume Avg (30-Day) 390
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 7,668
  • Open Int (30-Day) 7,087
  • Expected Range 5.01 to 7.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.07
  • Number of Estimates 5
  • High Estimate $-0.53
  • Low Estimate $-1.37
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -101.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.84 +5.31%
on 06/18/26
8.49 -27.56%
on 05/29/26
-0.75 (-10.87%)
since 05/18/26
3-Month
5.84 +5.31%
on 06/18/26
11.88 -48.23%
on 03/19/26
-5.57 (-47.53%)
since 03/18/26
52-Week
5.84 +5.31%
on 06/18/26
50.40 -87.80%
on 10/02/25
-23.88 (-79.52%)
since 06/18/25

Most Recent Stories

More News
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics Q1 Earnings Call Highlights

LENZ Therapeutics (NASDAQ:LENZ) reported first-quarter 2026 results that showed continued prescription growth for its presbyopia eye drop VIZZ, while management acknowledged that new patient adoption and...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch...

LENZ : 6.15 (-3.00%)
Lenz Therapeutics: Can VIZZ Script Volume Justify the Commercialization Burn Rate This Quarter?

Barchart Research What to Expect from LENZ Earnings LENZ Generated May 8, 2026 Current Price $10.06 EPS Estimate $$-1.10 Consensus Rating Strong Buy Average Move 8.30% Lenz Therapeutics: Can VIZZ Script...

LENZ : 6.15 (-3.00%)
Lenz Therapeutics: Can VIZZ Script Volume Justify the Commercialization Burn Rate This Quarter?

Barchart Research What to Expect from LENZ Earnings LENZ Generated May 8, 2026 Current Price $10.06 EPS Estimate $$-1.10 Consensus Rating Strong Buy Average Move 8.30% Lenz Therapeutics: Can VIZZ Script...

LENZ : 6.15 (-3.00%)
Lenz Therapeutics: Can VIZZ Script Volume Justify the Commercialization Burn Rate This Quarter?

Barchart Research What to Expect from LENZ Earnings LENZ Generated May 8, 2026 Current Price $10.06 EPS Estimate $$-1.10 Consensus Rating Strong Buy Average Move 8.30% Lenz Therapeutics: Can VIZZ Script...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE)...

LENZ : 6.15 (-3.00%)
LENZ Therapeutics Faces Critical Test as Losses Widen and Stock Plunges

LENZ : 6.15 (-3.00%)

Business Summary

Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical...

See More

Key Turning Points

3rd Resistance Point 7.23
2nd Resistance Point 6.89
1st Resistance Point 6.52
Last Price 6.15
1st Support Level 5.81
2nd Support Level 5.47
3rd Support Level 5.10

See More

52-Week High 50.40
Fibonacci 61.8% 33.38
Fibonacci 50% 28.12
Fibonacci 38.2% 22.86
Last Price 6.15
52-Week Low 5.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.